ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0206

Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada

kevin boehnke1, Ying He1, Tristin Smith1, marc martel2, david williams1 and Mary-Ann Fitzcharles3, 1University of Michigan, Ann Arbor, MI, 2McGill University, Montréal-Ouest, Canada, 3McGill University, Montréal, QC, Canada

Meeting: ACR Convergence 2022

Keywords: pain, Therapy, complementary

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Medical cannabis (MC) is increasingly used by persons with rheumatic conditions worldwide, although legal status varies by country. In Canada, MC has been federally available for over 2 decades, while 37 states in the United States (US) legalized MC since 1996. Similarly, recreational cannabis was federally legalized in Canada in 2018, whereas recreational use is currently legalized in 19 states in the US but remains federally illegal. In this study, we sought to understand whether and how these legal differences affected rationale for MC use and patient-physician interactions around MC between individuals residing in the US and Canada.

Methods: Partnering with the Arthritis Foundation (US) and the Arthritis Society (Canada), we surveyed persons self-reporting a rheumatic condition about MC use. Our final sample included n=459 participants in the US and n=347 in Canada. Excluded were those under 18, residing in a country outside US or Canada, not fluent in English or French, without a rheumatic condition, and failing to provide consent, or completion of the survey. We used R (version 4.1.1) for statistical analyses. Differences between subgroups were assessed using Pearsons’ Chi-square tests with Yates’ continuity correction for categorical variables and two sample t-tests for continuous variables.

Results: Compared to those in Canada, participants in the US were younger (55.5 vs. 63.6, p< 0.0001) and a higher proportion were female (89.5% vs. 77.5%, p < 0.0001) (Table 1). The distribution of race, educational level, employment status, tobacco use, and alcohol use were significantly different between countries (p’s < 0.05). Participants generally initiated cannabis use due to inadequate relief from medications or personal research. Compared to Canadian participants, a lower proportion of US participants obtained a MC license, initiated use due to physician recommendation, disclosed MC use to their physician, and asked for advice on how to use cannabis (all p’s < 0.001). Among participants who disclosed MC use to their physician, there were no significant differences between countries in perceptions of physician comfort or knowledge around MC (p’s >0.05). However, Canadian participants generally received more physician help on optimizing MC use (e.g., routes of administration (45% vs 35%), dosing (48.5% vs 22.4%), content of products (52.5% vs 31.3%), while US participants asked more questions about general safety (46.3% vs. 38.4%) and medication interactions (37.3% vs. 24.2%).

Conclusion: There are considerable differences between the US and Canada regarding the demographics of rheumatology patients using MC. Canadian patients report a greater dialogue with their physicians regarding MC use, although there were no differences in perceptions of physician knowledge or comfort with cannabis between countries. Our results suggest that MC legality may lower stigma and barriers to patient-physician communication about MC use.

Supporting image 1

Table1. Demographic Characteristics of US and Canada Patients Currently using Medical Cannabis

Supporting image 2


Disclosures: k. boehnke, Tryp therapeutics; Y. He, None; T. Smith, None; m. martel, Sant cannabis; d. williams, Swing therapeutics; M. Fitzcharles, None.

To cite this abstract in AMA style:

boehnke k, He Y, Smith T, martel m, williams d, Fitzcharles M. Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/differences-in-medicinal-cannabis-use-according-to-demography-rationale-and-patient-physician-interactions-between-the-united-states-and-canada/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-medicinal-cannabis-use-according-to-demography-rationale-and-patient-physician-interactions-between-the-united-states-and-canada/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology